Patents by Inventor Wolfgang Staehle

Wolfgang Staehle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sulfonamides
    Patent number: 7528139
    Abstract: Compounds of the formula (I), in which R6, R7, R8, R9 and X have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.
    Type: Grant
    Filed: March 17, 2005
    Date of Patent: May 5, 2009
    Assignee: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Guenter Hoelzemann, Helene Crassier, Alfred Jonczyk, Wolfgang Staehle, Wilfried Rautenberg
  • BENZIMIDAZOLES
    Publication number: 20090082404
    Abstract: Novel compounds of the formula I in which R1, R1?, L, E, G, M, Q, U, R2, m, p and q have the meanings indicated in Claim 1 and are, for example, inhibitors of tyrosine kinases, for example TIE-2, and can be employed, for example, for the treatment of tumours or other diseases.
    Type: Application
    Filed: December 4, 2008
    Publication date: March 26, 2009
    Applicant: MERCK PATENT GMBH
    Inventors: Wolfgang STAEHLE, Hans-Peter Buchstaller, Alfred Jonczyk, Wilfried Rautenberg
  • Tetrahydroquinolines
    Publication number: 20090030028
    Abstract: Disclosed are compounds of formula (I), wherein W, R, R1, R2, R3, R4, R5, R6, and R7 have the meanings indicated in claim 1. Said compounds can be used for the treatment of tumors, among other things.
    Type: Application
    Filed: June 3, 2005
    Publication date: January 29, 2009
    Inventors: Kai Schiemann, David Bruge, Hans-Peter Buchstaller, Dirk Finsinger, Wolfgang Staehle, Christiane Amendt, Ulrich Emde, Frank Zenke
  • Benzimidazoles
    Patent number: 7470702
    Abstract: Novel compounds of the formula I in which R1, R1?, L, E, G, M, Q, U, R2, m, p and q have the meanings indicated. Further, the compounds of formula I can be used as, for example, inhibitors of tyrosine kinases, for example TIE-2 , and can be employed, for example, for the treatment of tumours or other diseases.
    Type: Grant
    Filed: October 14, 2004
    Date of Patent: December 30, 2008
    Assignee: Merck Patent GmbH
    Inventors: Wolfgang Staehle, Hans-Peter Buchstaller, Alfred Jonczyk, Wilfried Rautenberg
  • Tetrahydroquinoline Derivatives
    Publication number: 20080221118
    Abstract: Compounds of the formula I, in which s, k, I, W, R1, R2, R3, and U have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: May 31, 2006
    Publication date: September 11, 2008
    Inventors: Wolfgang Staehle, David Bruge, Kai Schiemann, Dirk Finsinger, Hans-Peter Buchstaller, Frank Zenke, Christiane Amendt
  • Phenylurea Derivatives As Inhibitors Of Tyrosine Kinases For The Treatment Of Tumour Diseases
    Publication number: 20080207682
    Abstract: Compounds of the formula (I), in which R1a-R1e, R2a, R2b, R3 and X have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: September 16, 2005
    Publication date: August 28, 2008
    Applicant: Merck Patent GmbH
    Inventors: Wolfgang Staehle, Guenter Hoelzemann, Wilfried Rautenberg
  • Novel Azaheterocyclic Compounds as Kinase Inhibitors
    Publication number: 20080176892
    Abstract: The invention relates to compounds of the formula (I), to the preparation and use thereof for the preparation of a medicament for the treatment of diseases, in particular tumours and/or diseases in the development or course of which kinases are involved.
    Type: Application
    Filed: March 30, 2006
    Publication date: July 24, 2008
    Inventors: Timo Heinrich, Andree Blaukat, Wolfgang Staehle, Hartmut Greiner, Maria Kordowicz
  • N,N'-Diphenylurea Derivatives Which are Suitable as Kinase Inhibitors
    Publication number: 20080114026
    Abstract: Compounds of the formula (I), in which R1a—R1c, R2a, R2b, R3 and R5 have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: October 4, 2005
    Publication date: May 15, 2008
    Applicant: Merck Patent GmbH
    Inventors: Wolfgang Staehle, Guenter Hoelzemann, Wilfried Rautenberg
  • Sulfonamides
    Publication number: 20070244135
    Abstract: Compounds of the formula (I), in which R6, R7, R8, R9 and X have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: March 17, 2005
    Publication date: October 18, 2007
    Inventors: Guenter Hoelzemann, Helene Crassier, Alfred Jonczyk, Wolfgang Staehle, Wilfried Rautenberg
  • Imidazole Derivatives
    Publication number: 20070225347
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, X and X? have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: March 15, 2005
    Publication date: September 27, 2007
    Applicant: Merck Patent GmbH
    Inventors: Guenter Hoelzemann, Helene Crassier, Alfred Jonczyk, Wolfgang Staehle, Arne Sutter, Wilfried Rautenberg, Francesc Mitjans, Elisabet Rosell-Vives, Jaume Adan, Marta Riera
  • Pyridopyrimidinones
    Publication number: 20070099910
    Abstract: The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and X? have the designations cited in patent claim 1. Said compounds are inhibitors of tyrosine kinases, especially TIE-2, and Raf kinases, and can, inter alia, be used for the treatment of tumours.
    Type: Application
    Filed: October 14, 2004
    Publication date: May 3, 2007
    Applicant: Merck Patent GmbH
    Inventors: Guenter Hoelzemann, Helene Crassier, Karl-August Ackermann, Wolfgang Staehle, Alfred Jonczyk, Wilfried Rautenberg, Francesc Mitjans, Elisabet Rosell-Vives, Jaume Adan, Marta Soler Riera
  • Aminobenzimidazole derivatives
    Publication number: 20070021456
    Abstract: Novel compounds of formula (I) are disclosed, where R1, R1?, L, Y, m and p have the meanings given in claim 1, which are inhibitors of tyrosine kinases, in particular, TIE-2 and Raf kinases and can be used for the treatment of tumors.
    Type: Application
    Filed: July 19, 2004
    Publication date: January 25, 2007
    Applicant: MERCK PATENT GMBH
    Inventors: Francesc Mitjans, Elisabet Rosel-Vives, Jaume Adan, Marta Soler, Guenter Hoelzemann, Helene Crassier, Karl-August Ackermann, Wolfgang Staehle, Alfred Jonczyk, Wilfried Rautenberg
  • 1,3-Benzoxazolyl derivatives as kinase inhibitors
    Publication number: 20060281762
    Abstract: The invention relates to compounds of formula 1, the production and use thereof as a medicament for the treatment of diseases, particularly tumours and/or diseases caused, mediated or propagated by angiogenesis. The compounds of formula 1 are effective inhibitors of tyrosin kinases, particularly TIE-2 and VEGFR, and Raf-kinases.
    Type: Application
    Filed: September 1, 2004
    Publication date: December 14, 2006
    Inventors: Wolfgang Staehle, Alfred Jonczyk, Wilfried Rautenberg
  • Inhibitors of integrin ??
    Patent number: 7138417
    Abstract: Novel biphenyl derivatives of the general formula I in which R1, R1?, R1?, R2, R2?, R3 and n are as defined in Patent claim 1, stereoisomers thereof and physiologically acceptable salts or solvates thereof are novel integrin inhibitors which preferentially inhibit the ?v?6 integrin receptor.
    Type: Grant
    Filed: January 15, 2003
    Date of Patent: November 21, 2006
    Assignee: Merck Patent GmbH
    Inventors: Wolfgang Staehle, Oliver Schadt, Alfred Jonczyk, Simon Goodman
  • Urea and urethane derivatives as integrin inhibitors
    Patent number: 7135587
    Abstract: Novel urea and urethane derivatives of general formula (I) in which R1, R2, R3, R5, R5?, X, Y, B, m, n and o are as defined in Patent Claim 1, and physiologically acceptable salts or solvates thereof are integrin inhibitors and can be employed for combating thromboses, cardiac infarction, coronary heart disease, arteriosclerosis, inflammation, tumors. Osteoporosis, infections and restenosis after angioplasty or in pathological processes maintained or propagated by antiogenesis.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: November 14, 2006
    Assignee: Merck Patent GmbH
    Inventors: Wolfgang Staehle, Alfred Jonczyk, Oliver Schadt, Simon Goodman
  • Urea derivatives and their use as tyrosinkinase inhibitors
    Publication number: 20060241301
    Abstract: The invention relates to novel urea derivatives which inhibit tyrosinkinases, especially TIE-2, and Raf kinases and which are used in the treatment of tumors.
    Type: Application
    Filed: July 2, 2004
    Publication date: October 26, 2006
    Inventors: Gunter Hoelzemann, Karl-August Ackermann, Wolfgang Staehle, Alfred Jonczyk, Wilfried Rautenberg, Helerie Crassier, Francesc Mitjans, Elisabet Rosell-Vives, Jaume Adan, Marta Soler Riera
  • Inhibitors of integrin avb6
    Publication number: 20050153902
    Abstract: Novel biphenyl derivatives of the general formula I in which R1, R1?, R1?, R2, R2?, R3 and n are as defined in Patent claim 1, stereoisomers thereof and physiologically acceptable salts or solvates thereof are novel integrin inhibitors which preferentially inhibit the ?v?6 integrin receptor. The novel compounds can be used, in particular, as medicaments.
    Type: Application
    Filed: January 15, 2003
    Publication date: July 14, 2005
    Inventors: Wolfgang Staehle, Oliver Schadt, Alfred Jonczyk, Simon Goodman
  • Ligands of the $g(a)v$g(b)6 integrin
    Publication number: 20040142877
    Abstract: Novel biphenyl derivatives of the general formula I 1
    Type: Application
    Filed: October 14, 2003
    Publication date: July 22, 2004
    Inventors: Oliver Schadt, Alfred Jonczyk, Wolfgang Staehle, Simon Goodman
  • &bgr;-alanine derivatives
    Patent number: 6576637
    Abstract: The invention relates to &bgr;-alanine derivatives of formula (I), wherein Q1, Q2, Q3, Q4, R1, R2, R3, R4, R5, R6 and n have the meaning as disclosed in the disclosure, and to their physiologically acceptable salts or solvates. Said substances are integrin inhibitors and can be used in the treatment of thrombosis, heart infarct, coronary heart diseases, arteriosclerosis, inflammations, tumors, osteoporosis, infections and restenosis after angioplasty or in pathological processes induced or propagated by angiogenesis.
    Type: Grant
    Filed: August 20, 2001
    Date of Patent: June 10, 2003
    Assignee: Merck Patent GmbH
    Inventors: Günter Hölzemann, Simon Goodmann, Alfred Jonczyk, Wolfgang Stähle
  • Dibenzoazulene derivatives for treating thrombosis, osteoporosis, arteriosclerosis
    Patent number: 6521646
    Abstract: Compounds of the formula (I) and their physiologically acceptable salts and solvates are useful as integrin-inhibiting substances. They are especially useful in the prophylaxis and treatment of cardiovascular disorders, of thrombosis, cardiac infarction, coronary heart diseases, arteriosclerosis, osteoporosis, in pathological conditions that are caused or propagated by angiogenesis and in tumor therapy.
    Type: Grant
    Filed: October 15, 2001
    Date of Patent: February 18, 2003
    Assignee: Merck Patent GmbH
    Inventors: Wolfgang Stähle, Rudolf Gottschlich, Simon Goodman